FXIII Inhibitor Composition Using C-Terminal Michael Acceptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development for targeting coagulation factor XIII (FXIII) lacks potent and selective inhibitors, which are crucial for preventing venous thromboembolism and treating conditions like acute coronary syndrome without increasing bleeding risk.
Innovation Solution
Development of peptidomimetic inhibitors with a Michael-acceptor warhead, specifically positioned at the C-terminus, that irreversibly inactivate FXIIIa, ensuring high selectivity and minimal side effects by positioning the warhead optimally within the active site cysteine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anticoagulants block thrombin or upstream FXa, then venous thromboembolism prevention is achieved, but bleeding risk is enhanced
Solution Approach 1:
The patent extracts the inhibitory function from the thrombin pathway and relocates it to FXIII, a downstream target. By developing selective FXIII inhibitors that do not interfere with thrombin generation or fibrin formation, the harmful bleeding side effects are eliminated while maintaining thromboprevention efficacy through targeted clot stabilization inhibition
Solution Approach 2:
The patent changes the target parameter from thrombin/FXa inhibition to FXIII inhibition. This parameter change shifts the mechanism of action from preventing clot formation to stabilizing existing clots, thereby achieving thromboprevention without the bleeding risk associated with upstream coagulation factor inhibition
2Reliability
If peptidic inhibitors with Michael-acceptor warhead are designed, then FXIIIa selectivity and potency are improved, but synthesis complexity increases
Solution Approach 1:
The inhibitor molecule is segmented into distinct functional modules: a peptidic backbone for substrate recognition and binding, and a C-terminal Michael-acceptor warhead for irreversible covalent modification of the active site cysteine. This segmentation allows each module to be optimized independently for its specific function while simplifying the overall synthesis through modular assembly
Solution Approach 2:
The peptidic backbone acts as an intermediary that positions the Michael-acceptor warhead precisely at the active site cysteine of FXIIIa. This intermediary structure enables selective binding and orientation, ensuring that the reactive warhead only interacts with the target enzyme's catalytic cysteine, thereby achieving high selectivity and potency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibitors effectively inhibit FXIIIa with minimal side effects, providing a therapeutic option for conditions associated with FXIII while avoiding interference with thrombin generation or fibrin formation, thus reducing bleeding risks.
Implementation Method 1
irreversibly inactivate FXIIIa, ensuring high selectivity and minimal side effects by positioning the warhead optimally within the active site cysteine
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The invention relates to a compound of general formula (I) as novel inhibitor of blood coagulation factor XIII, methods for synthesis thereof and to use thereof for the prophylaxis or treatment of diseases associated with blood coagulation factor XIII.